Difference between revisions of "Antithymocyte globulin, horse ATG (Atgam)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Immunosuppresants" to "Category:Immunosuppressants") |
m |
||
| (11 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Contains antibodies against T-cell markers including CD2, CD3, CD4, CD8, CD11a, CD18, CD25, CD44, CD45, Beta-2 microglobulin, HLA Class I heavy chains, and HLA-DR. Exact mechanism not understood, but may involve removing T-cells from circulation and modifying T-cell activation, migration, proliferation, and cytotoxic effects.<ref name="insert">[http://labeling.pfizer.com/ShowLabeling.aspx?id=525 Antithymocyte globulin, horse ATG (Atgam) package insert]</ref><ref>[[ | + | Class/mechanism: Contains antibodies against T-cell markers including CD2, CD3, CD4, CD8, CD11a, CD18, CD25, CD44, CD45, Beta-2 microglobulin, HLA Class I heavy chains, and HLA-DR. Exact mechanism not understood, but may involve removing T-cells from circulation and modifying T-cell activation, migration, proliferation, and cytotoxic effects.<ref name="insert">[http://labeling.pfizer.com/ShowLabeling.aspx?id=525 Antithymocyte globulin, horse ATG (Atgam) package insert]</ref><ref>[[File:Antithymocyteglobulinhorse.pdf | Antithymocyte globulin, horse ATG (Atgam) package insert (locally hosted backup)]]</ref><ref>[http://www.pfizer.com/products/rx/rx_product_atgam.jsp Atgam manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://reference.medscape.com/drug/atgam-atg-equine-antithymocyte-globulin-equine-343190 Medscape], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Aplastic anemia]] | *[[Aplastic anemia]] | ||
| + | *[[Graft versus host disease]] | ||
| + | *[[Myelodysplastic syndrome]] | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://www.uptodate.com/contents/horse-antithymocyte-globulin-atgam-patient-drug-information Antithymocyte globulin, horse ATG (Atgam) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/horse-antithymocyte-globulin-atgam-patient-drug-information Antithymocyte globulin, horse ATG (Atgam) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/horse-antithymocyte-globulin-atgam-patient-drug-information Antithymocyte globulin, horse ATG (Atgam) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/horse-antithymocyte-globulin-atgam-patient-drug-information Antithymocyte globulin, horse ATG (Atgam) patient drug information (UpToDate)]</ref> | ||
| − | + | ==History of changes in EMA indication== | |
| + | *1981-11-17: EURD | ||
==Also known as== | ==Also known as== | ||
| − | + | ''Note: different brands of horse ATG are likely to be from different host animals and will thus have different constituents; they should not be considered necessarily interchangeable.'' | |
| + | *'''Brand names:''' Atgam, Lymphoglobuline, Thymogam | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| − | |||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Fractionated plasma products]] | [[Category:Fractionated plasma products]] | ||
| − | [[Category: | + | [[Category:Antithymocyte globulin]] |
| − | [[Category: | + | [[Category:Aplastic anemia medications]] |
| + | [[Category:Graft versus host disease medications]] | ||
| + | [[Category:Myelodysplastic syndrome medications]] | ||
| − | [[Category: | + | [[Category:EMA approved in 1981]] |
Latest revision as of 14:59, 15 June 2023
General information
Class/mechanism: Contains antibodies against T-cell markers including CD2, CD3, CD4, CD8, CD11a, CD18, CD25, CD44, CD45, Beta-2 microglobulin, HLA Class I heavy chains, and HLA-DR. Exact mechanism not understood, but may involve removing T-cells from circulation and modifying T-cell activation, migration, proliferation, and cytotoxic effects.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in EMA indication
- 1981-11-17: EURD
Also known as
Note: different brands of horse ATG are likely to be from different host animals and will thus have different constituents; they should not be considered necessarily interchangeable.
- Brand names: Atgam, Lymphoglobuline, Thymogam